{"pmid":32476285,"title":"Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.","text":["Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.","Universal screening of potential organ donors and recipients for SARS-CoV-2 is now recommended prior to transplantation in the United States during the COVID-19 pandemic. Challenges have included limited testing capacity, short windows of organ viability, brief lead time for notification of potential organ recipients, and the need to test lower respiratory donor specimens to optimize sensitivity. In an early US epicenter of the outbreak, we designed and implemented a system to expedite this testing and here report results from the first three weeks. The process included a Laboratory Medicine designee for communication with organ recovery and transplant clinical staff, specialized sample labeling and handoff, and priority processing. Thirty-two organs recovered from 14 of 17 screened donors were transplanted versus 70 recovered from 23 donors during the same period in 2019. No pre-transplant or organ donors tested positive for SARS-CoV-2. Median turnaround time from specimen receipt was 6.8h (donors), 6.5h (recipients): 4.5h faster than daily inpatient median. No organ recoveries or transplants were disrupted by a lack of SARS-CoV-2 testing. Waitlist inactivations for COVID-19 precautions were reduced in our region. Systems that include specialized ordering pathways and adequate testing capacity can support continued organ transplantation even in a SARS-CoV-2 hyperendemic area.","Am J Transplant","Lieberman, Joshua A","Mays, James A","Wells, Candy","Cent, Anne","Bell, Deborah","Bankson, Daniel D","Greninger, Alex L","Jerome, Keith R","Limaye, Ajit P","32476285"],"abstract":["Universal screening of potential organ donors and recipients for SARS-CoV-2 is now recommended prior to transplantation in the United States during the COVID-19 pandemic. Challenges have included limited testing capacity, short windows of organ viability, brief lead time for notification of potential organ recipients, and the need to test lower respiratory donor specimens to optimize sensitivity. In an early US epicenter of the outbreak, we designed and implemented a system to expedite this testing and here report results from the first three weeks. The process included a Laboratory Medicine designee for communication with organ recovery and transplant clinical staff, specialized sample labeling and handoff, and priority processing. Thirty-two organs recovered from 14 of 17 screened donors were transplanted versus 70 recovered from 23 donors during the same period in 2019. No pre-transplant or organ donors tested positive for SARS-CoV-2. Median turnaround time from specimen receipt was 6.8h (donors), 6.5h (recipients): 4.5h faster than daily inpatient median. No organ recoveries or transplants were disrupted by a lack of SARS-CoV-2 testing. Waitlist inactivations for COVID-19 precautions were reduced in our region. Systems that include specialized ordering pathways and adequate testing capacity can support continued organ transplantation even in a SARS-CoV-2 hyperendemic area."],"journal":"Am J Transplant","authors":["Lieberman, Joshua A","Mays, James A","Wells, Candy","Cent, Anne","Bell, Deborah","Bankson, Daniel D","Greninger, Alex L","Jerome, Keith R","Limaye, Ajit P"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476285","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16081","keywords":["covid-19","organ transplant","sars-cov-2","rapid testing","turnaround time"],"locations":["United States","US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1668532089457213440,"score":9.490897,"similar":[{"pmid":32400087,"title":"Use of SARS-CoV-2 infected deceased organ donors: Should we always \"just say no?\"","text":["Use of SARS-CoV-2 infected deceased organ donors: Should we always \"just say no?\"","In the context of a rapidly evolving pandemic, multiple organizations have released guidelines stating that all organs from potential deceased donors with SARS-CoV-2 infection should be deferred, including from otherwise medically eligible donors found to have mild or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this manuscript, we critically examine the available data on the risk of transmission of SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from non-lung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens, previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA respiratory viruses are all addressed. Taken together, these data provide little evidence to suggest the presence of intact transmissible SARS-CoV in organs that can potentially be transplanted, specifically liver and heart. Other considerations including ethical, financial, societal, and logistical concerns are also addressed. We conclude that, for selected patients with high waitlist mortality, transplant programs should consider accepting heart or liver transplants from deceased donors with SARS-CoV-2 infection.","Am J Transplant","Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P","32400087"],"abstract":["In the context of a rapidly evolving pandemic, multiple organizations have released guidelines stating that all organs from potential deceased donors with SARS-CoV-2 infection should be deferred, including from otherwise medically eligible donors found to have mild or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this manuscript, we critically examine the available data on the risk of transmission of SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from non-lung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens, previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA respiratory viruses are all addressed. Taken together, these data provide little evidence to suggest the presence of intact transmissible SARS-CoV in organs that can potentially be transplanted, specifically liver and heart. Other considerations including ethical, financial, societal, and logistical concerns are also addressed. We conclude that, for selected patients with high waitlist mortality, transplant programs should consider accepting heart or liver transplants from deceased donors with SARS-CoV-2 infection."],"journal":"Am J Transplant","authors":["Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400087","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16000","topics":["Prevention"],"weight":1,"_version_":1666714494909284352,"score":451.372},{"pmid":32323460,"title":"Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach.","text":["Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach.","The ongoing SARS-CoV-2 pandemic has a drastic impact on national healthcare systems. Given the overwhelming demand of facility capacity, the impact on all healthcare sectors has to be addressed. Solid organ transplantation represents a field with a high demand on staff, intensive care units and follow-up facilities. The great therapeutic value of organ transplantation has to be weighed against mandatory constraints of healthcare capacities. In addition, the management of immunosuppressed recipients has to be reassessed during the ongoing COVID-19 pandemic. In addressing these crucial questions, transplant physicians are facing a total lack of scientific evidence. Therefore, the aim of this study was to offer an approach of consensus-based guidance, derived from individual information of 22 transplant societies. Key recommendations were extracted and the degree of consensus among different organizations was calculated. A high degree of consensus was found for temporarily suspending non-urgent transplant procedures and living donation programs. Systematic PCR-based testing of donors and recipients was broadly recommended. Additionally, more specific aspects (e.g., screening of surgical explant teams and restricted use of marginal donor organs) were included in our analysis. This study offers a novel approach on informed guidance for healthcare management when a priori no scientific evidence is available.","Am J Transplant","Ritschl, Paul Viktor","Nevermann, Nora","Wiering, Leke","Wu, Helen Hairun","Morodor, Philipp","Brandl, Andreas","Hillebrandt, Karl","Tacke, Frank","Friedersdorff, Frank","Schlomm, Thorsten","Schoning, Wenzel","Ollinger, Robert","Schmelzle, Moritz","Pratschke, Johann","32323460"],"abstract":["The ongoing SARS-CoV-2 pandemic has a drastic impact on national healthcare systems. Given the overwhelming demand of facility capacity, the impact on all healthcare sectors has to be addressed. Solid organ transplantation represents a field with a high demand on staff, intensive care units and follow-up facilities. The great therapeutic value of organ transplantation has to be weighed against mandatory constraints of healthcare capacities. In addition, the management of immunosuppressed recipients has to be reassessed during the ongoing COVID-19 pandemic. In addressing these crucial questions, transplant physicians are facing a total lack of scientific evidence. Therefore, the aim of this study was to offer an approach of consensus-based guidance, derived from individual information of 22 transplant societies. Key recommendations were extracted and the degree of consensus among different organizations was calculated. A high degree of consensus was found for temporarily suspending non-urgent transplant procedures and living donation programs. Systematic PCR-based testing of donors and recipients was broadly recommended. Additionally, more specific aspects (e.g., screening of surgical explant teams and restricted use of marginal donor organs) were included in our analysis. This study offers a novel approach on informed guidance for healthcare management when a priori no scientific evidence is available."],"journal":"Am J Transplant","authors":["Ritschl, Paul Viktor","Nevermann, Nora","Wiering, Leke","Wu, Helen Hairun","Morodor, Philipp","Brandl, Andreas","Hillebrandt, Karl","Tacke, Frank","Friedersdorff, Frank","Schlomm, Thorsten","Schoning, Wenzel","Ollinger, Robert","Schmelzle, Moritz","Pratschke, Johann"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323460","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15933","topics":["Prevention"],"weight":1,"_version_":1666138493919690752,"score":438.89755},{"pmid":32368850,"title":"Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.","text":["Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.","SARS-CoV-2 has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained healthcare resources and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplantation continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of COVID-19 positive donors in selected cases. We present a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The factors we consider include: 1) the risk of blood transmission SARS-CoV-2, 2) involvement of donor organs, 3) lack of effective therapies, 4) exposure of healthcare and recovery teams, 5) disease transmission and propagation, and 6) hospital resource utilization. While we acknowledge that transplantation fulfills the mission of saving lives, it is imperative to consider the consequences not only to our recipients, but also to the community and to healthcare workers, particularly in the absence of effective preventative or curative therapies. For these reasons, we believe the evidence and risks show that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.","Am J Transplant","Shah, Malay B","Lynch, Raymond J","El-Haddad, Hanine","Doby, Brianna","Brockmeier, Diane","Goldberg, David S","32368850"],"abstract":["SARS-CoV-2 has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained healthcare resources and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplantation continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of COVID-19 positive donors in selected cases. We present a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The factors we consider include: 1) the risk of blood transmission SARS-CoV-2, 2) involvement of donor organs, 3) lack of effective therapies, 4) exposure of healthcare and recovery teams, 5) disease transmission and propagation, and 6) hospital resource utilization. While we acknowledge that transplantation fulfills the mission of saving lives, it is imperative to consider the consequences not only to our recipients, but also to the community and to healthcare workers, particularly in the absence of effective preventative or curative therapies. For these reasons, we believe the evidence and risks show that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies."],"journal":"Am J Transplant","authors":["Shah, Malay B","Lynch, Raymond J","El-Haddad, Hanine","Doby, Brianna","Brockmeier, Diane","Goldberg, David S"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368850","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15969","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138496232849409,"score":437.77054},{"pmid":32282986,"title":"Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","text":["Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.","Am J Transplant","Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa","32282986"],"abstract":["Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients."],"journal":"Am J Transplant","authors":["Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282986","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15928","keywords":["covid-19","clinical characteristics","immunosuppressant","solid organ transplant recipient"],"e_drugs":["Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138491464974336,"score":399.9132},{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","tocilizumab","Azithromycin"],"topics":["Prevention"],"weight":1,"_version_":1666138491535228928,"score":397.5753}]}